Health-Care Costs Spiking: Employers Face 8.5% Increase in 2026

Key Takeaways

• Employer health-care costs rose 8.5% in 2026 — the sharpest increase since 2021.
• GLP-1 weight-loss drugs (Wegovy, Zepbound) alone account for 1.9 percentage points of that increase.
• Average annual cost per employee for these drugs: $1,240/month before insurance negotiation.
• 40% of employers plan to restrict access or move GLP-1 drugs to specialty tiers in 2027.
• Employees should check formulary changes before open enrollment — coverage may shift mid-year.

---

Why Your Company’s Health Plan Got More Expensive

If you’ve noticed higher payroll deductions or fewer benefits options this year, there’s a reason:

Employers across the U.S. are paying 8.5% more for health-care coverage in 2026 — the biggest jump since 2021.

And a surprising culprit tops the list: weight-loss drugs.

Specifically, the GLP-1 agonists like Wegovy and Mounjaro.

The Numbers Behind the Surge

According to Mercer's 2026 Health Trends Survey, employers paid an average of $15,400 per employee for health benefits in 2026. That’s up $1,240 from 2025.

Breaking that down:

• GLP-1 drugs accounted for 1.9 percentage points of the 8.5% total increase
• Other drivers: specialty generics (-0.3%), physician services (+2.1%), hospital care (+1.8%)

For companies with 500+ employees, GLP-1 spending alone added $620,000 annually to benefit budgets.

The Formulary Arms Race

Drug manufacturers list GLP-1s at roughly $1,300/month retail. Even with insurance negotiation, employers still pay an average of $1,240/month per patient.

Most insurers now require:

• Prior authorization for anyone without diabetes
• Step therapy (try cheaper appetite suppressants first)
• BMI thresholds ≥30 with comorbidities

How Companies Are Responding

1. Restrictive Formularies

Some employers are switching GLP-1s from a preferred tier to specialty-only access — making patients pay 30–50% coinsurance instead of a $10–$20 copay.

2. Outcome-Based Contracts

Forward-thinking plans tie reimbursement to measurable weight loss — typically 10–15% reduction over 12 months. If patients don’t meet targets, manufacturers must offer partial refunds.

3. In-House Pharmacy Programs

Companies like Amazon and Costco now dispense GLP-1s directly, cutting out pharmacy benefit managers who add 15–20% markups.

What Employees Should Know Before Open Enrollment

1. Check your formulary early — don’t assume last year’s coverage applies
2. Ask HR about prior authorization requirements if you're on or considering GLP-1 therapy
3. Inquire about flexible spending accounts (FSAs) — some now include weight-loss drugs as eligible expenses
4. Understand step therapy — you may need documented failed attempts with cheaper alternatives first

Frequently Asked Questions

Q: Will my company drop GLP-1 coverage entirely?

Unlikely — but they may restrict it to diabetes indications only by 2027.

Q: How do compounding pharmacies affect costs?

Compounded versions cost $20–$80/month but lack FDA oversight. Several have been recalled for contamination.

Q: What’s the alternative to GLP-1 drugs?

Orlistat, phentermine-topiramate, and newer dual agonists are in development but aren’t yet widely available.

GLP-1 muscle loss explains how these drugs affect body composition beyond weight.

Source: Mercer 2026 Health Trends Survey. Medical cost trend averaged 8.5% in 2026, with GLP-1 weight-loss drugs contributing 1.9 percentage points. Companies spending $1,240/month per employee on these drugs.